Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
Ansar A. Pathan, Clare R. Sander, Helen A. Fletcher et al. · 2007
Read Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials by Ansar A. Pathan, Clare R. Sander, Helen A. Fletcher et al. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0001052.txt.
Description
Ansar Pathan, Clare Sander, Helen Fletcher and colleagues tested boosting the TB vaccine with a modified virus, in PLOS ONE in 2007. BCG is the standing tuberculosis vaccine, and its protection fades. The booster candidate, MVA85A, is a modified vaccinia virus carrying a TB antigen called 85A.
The team investigated the safety and immune effects of giving the boost shortly after BCG. They compared results with BCG alone and with an earlier trial using a longer interval. Timing can make or break a booster, since the first vaccine's response is still rising. Their comparison helps set the schedule for larger efficacy trials.
Catalog record
| CREATOR | Ansar A. Pathan, Clare R. Sander, Helen A. Fletcher et al. |
|---|---|
| YEAR | 2007 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001052